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Pathological alterations to the locus coeruleus, the major source of noradrenaline in the brain, are histologically evident in early stages of
neurodegenerative diseases. Novel MRI approaches now provide an opportunity to quantify structural features of the locus coeruleus
in vivo during disease progression. In combination with neuropathological biomarkers, in vivo locus coeruleus imaging could help to
understand the contribution of locus coeruleus neurodegeneration to clinical and pathological manifestations in Alzheimer’s disease,
atypical neurodegenerative dementias and Parkinson’s disease. Moreover, as the functional sensitivity of the noradrenergic system is
likely to change with disease progression, in vivo measures of locus coeruleus integrity could provide new pathophysiological insights
into cognitive and behavioural symptoms. Locus coeruleus imaging also holds the promise to stratify patients into clinical trials
according to noradrenergic dysfunction. In this article, we present a consensus on how non-invasive in vivo assessment of locus coeruleus
integrity can be used for clinical research in neurodegenerative diseases. We outline the next steps for in vivo, post-mortem and clinical
studies that can lay the groundwork to evaluate the potential of locus coeruleus imaging as a biomarker for neurodegenerative diseases.
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Introduction
The number of individuals over the age of 60 years is pro-
jected to rise from 841 million in 2013 to over 2 billion by
2050 (World Population Ageing report, United Nations).
As the population has continued to age, age-related neuro-
degenerative diseases have already reached epidemic pro-
portions. Whilst numerous therapeutic strategies are being
investigated, current treatments provide only modest symp-
tomatic relief and do not slow or halt ensuing neurodegen-
eration. A major priority is to develop early disease stage
biomarkers that can improve the understanding of the
pathophysiology of neurodegenerative diseases, enable ear-
lier detection of pathology and facilitate the application of
timely symptomatic interventions.
The locus coeruleus (LC) is the major source of nor-
adrenaline modulation in the brain and has been shown
to be involved in regulating a wide range of higher cogni-
tive functions, such as working memory, learning and at-
tention (Robbins, 1984; Aston-Jones and Cohen, 2005;
Benarroch, 2009; Mather et al., 2016), memory consolida-
tion and retrieval (Sterpenich et al., 2006; Sara, 2009),
vigilance, arousal/wakefulness, rapid eye movement
(REM) sleep behaviour, pain modulation, local blood
flow and immunological mechanisms in the brain (Aston-
Jones and Bloom, 1981; Benarroch, 2009; Espay et al.,
2014; Heneka et al., 2015; O’Donnell et al., 2015).
Conversely, age-related decline within the LC–nor-
adrenergic system is associated with reduced cognitive abil-
ities relating to episodic memory (Ha¨mmerer et al., 2018,
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Jacobs et al., 2018b; Dahl et al., 2019) and reduced cog-
nitive reserve (Robertson, 2013; Wilson et al., 2013;
Clewett et al., 2016; Mather and Harley, 2016). In
Alzheimer’s disease, tau aggregates are observed first in
the LC, prior to their presence in transentorhinal/entorhinal
cortex and neocortex (Braak et al., 2011; Stratmann et al.,
2016; Andre´s-Benito et al., 2017; Ehrenberg et al., 2017).
In Parkinson’s disease, intraneuronal -synuclein burden in
the LC precedes and may be of even greater magnitude
than that in the dopaminergic substantia nigra pars com-
pacta (SNpc) (Braak et al., 2003; Dickson et al., 2008). As
a result, the degree of Parkinson’s disease-related neuronal
loss is likely just as severe in the LC as in the SNpc (Zarow
et al., 2003; Gigue`re et al., 2018). Pathological changes in
the LC have also been reported in other neurodegenerative
and neuropsychiatric conditions (Box 1), leading to the
notion that the LC may be a vulnerable target for path-
ology (Sharma et al., 2010). Whether this is related to LC
neurons’ high metabolic need in order to maintain essential
physiological functions or the close proximity of the LC to
the fourth ventricle, exposing it to toxins from the CSF
(Mather and Harley, 2016; Weinshenker, 2018), remains
to be determined.
With the notable exception of most of the basal ganglia, the
LC projects to large portions of subcortical and cortical areas
(Berridge and Waterhouse, 2003). Moreover, reminiscent of
Box 1 Role of the LC in neurological disorders
Structural and functional changes in the human LC leading to deficits in noradrenaline may contribute to the pathophysiology and symptomatology
of several neurological disorders:
Alzheimer’s disease
Deposition of tau in and degeneration of the LC occurs early in the asymptomatic phase of Alzheimer’s disease (Braak and Del Tredici, 2012; Arendt
et al., 2015) suggesting that the LC is the initial site of pathology. Accumulation of tau (doubling from Braak stage 0 to 1; Ehrenberg et al., 2017) and
significant volume loss precede neuronal loss in the LC during Alzheimer’s disease progression (Theofilas et al., 2017). Depletion of up to 30% of LC
neurons has been reported in prodromal (mild cognitive impairment stage) Alzheimer’s disease, increasing to 55% with diagnosed dementia (Kelly
et al., 2017). Neuronal loss is particularly prevalent in the rostral/middle portion of the LC (German et al., 1992; Theofilas et al., 2017), correlating
with cognitive dysfunction including memory, perceptual speed, and visuo-spatial ability (Kelly et al., 2017), and with reduced noradrenaline levels in
hippocampus and cortex (Lyness, 2003). Compensatory activity, such as increased metabolism in surviving neurons or reorganization of functional
networks, can occur in early disease stages (Hoogendijk et al., 1999; Jacobs et al., 2015).
Synucleinopathies
In Parkinson’s disease and dementia with Lewy bodies, -synuclein containing Lewy bodies and neuronal cell loss are seen along the entire length of
the LC (German et al., 1992; Theofilas et al., 2017). Intraneuronal Lewy bodies also affect tyrosine hydroxylase (TH) activity, potentially interfering
with normal catecholamine biosynthesis (Tabrez et al., 2012), which may distinguish the effects of Parkinson’s disease/dementia with Lewy bodies
from Alzheimer’s disease (McMillan et al., 2011). It has also been postulated that LC burden precedes substantia nigra involvement in Parkinson’s
disease (Zarow et al., 2003; Braak et al., 2004; Seidel et al., 2015), rendering the LC a good candidate for preclinical diagnosis (Liu et al., 2017).
However, the field lacks a comprehensive analysis detailing the stages of neuronal loss in Parkinson’s disease.
Multiple system atrophy (MSA) is another heterogeneous -synucleinopathy, in which autonomic dysfunction, parkinsonism, and ataxia (Stankovic et al.,
2014; Walsh et al., 2018) are associated with severe neuronal loss in the LC and noradrenergic cardiorespiratory brainstem nuclei (A5, A1) (Benarroch
et al., 2008). An in vivo neuromelanin-sensitive MRI study has shown that LC contrast is reduced in MSA compared to healthy controls and that the ratio
of neuromelanin-sensitive MRI contrast in substantia nigra versus LC could help distinguish MSA from Parkinson’s disease (Matsuura et al., 2013).
Patients with idiopathic rapid eye movement sleep disorder (iRBD) have a strongly increased risk of developing Parkinson’s disease, dementia with
Lewy bodies, MSA and mild cognitive impairment; 75.7% and 90.9% develop a neurodegenerative syndrome 10 and 14 years from the time of iRBD
diagnosis, respectively. Interestingly, iRBD is associated with dysfunction of the LC-noradrenergic system (Knudsen et al., 2018) suggesting that LC
imaging might serve as a valuable biomarker in patients at risk of developing neurodegenerative disease.
Chronic traumatic encephalopathy
In addition to early pathological affection of cortical sulci, substantial LC damage and tau accumulation has also been reported in early disease stages
(Stein et al., 2014). LC pathology may also exacerbate clinical presentation of cognitive complaints and mood disturbances in chronic traumatic
encephalopathy (Stern and Daneshvar, 2013).
Frontotemporal lobar degeneration
Modest LC neuronal loss occurs in both tau- and non-tau- forms of frontotemporal lobar degeneration (Brunnstro¨m et al., 2011; Eser et al., 2018),
both in early and late disease stages (Irwin et al., 2016). Clinically, the loss and dysregulation of noradrenaline from LC degeneration may contribute
to cognitive decline, including impulsivity and apathy (Passamonti et al., 2018).
Essential tremor
A neuropathological study (n = 33) revealed Lewy body pathology in the LC in 25% of the cases with essential tremor (Louis et al., 2007).
Noradrenergic LC-cerebellar connections are important for the normal function of Purkinje cells and their inhibitory output (Moises et al.,
1981). Degeneration and ensuing LC dysfunction may modulate Purkinje cell activity and contribute to decreased cerebellar inhibition in essential
tremor (Louis et al., 2007).
Non-degenerative, neuropsychiatric illnesses
LC dysfunction, also without neuronal loss, has also been implicated in post-traumatic stress disorder (Bernard et al., 2011; Pietrzak et al., 2013),
addiction (Bernard et al., 2011), depression (Berridge and Waterhouse, 2003), suicidal behaviour (Roy et al., 2017) and chronic pain (Llorca-Torralba
et al., 2016; Taylor and Westlund, 2017).
2560 | BRAIN 2019: 142; 2558–2571 M. J. Betts et al.
locally specific connectivity in dopaminergic nuclei (Haber and
Knutson, 2010), tracing studies in the rat suggest that there
might be distinct projections from rostrolateral LC to hippo-
campus, amygdala and septum (Van Bockstaele et al., 2006)
and from caudal aspects of the LC to the spinal cord (Ennis
et al., 1991). This may indicate a stronger involvement of
rostrolateral LC in modulating memory encoding and caudal
LC in modulating pain perception.
While the LC is among the first brain structures to demon-
strate pathology in neurodegenerative diseases, it currently re-
mains unclear how alterations in LC structure and function
influence pathogenesis and symptom progression. In human
studies, neuropsychiatric symptoms associated with LC activity,
such as sleep dysfunction, agitation, anxiety, appetite dysfunc-
tion and depression, appear as elements of the early clinical
phenotypes of neurodegenerative diseases (Assal and
Cummings, 2002; Lanctoˆt et al., 2017; Ehrenberg et al.,
2018). In animal models, lesions of the LC have been shown
to exacerbate tau and amyloid-b plaque deposition, leading to
depletion of noradrenaline in LC target regions and impaired
cognitive function (Heneka, 2006; Kalinin et al., 2006, 2012;
Jardanhazi-Kurutz et al., 2010; Chalermpalanupap et al., 2017;
Rorabaugh et al., 2017). Whether the influence of LC degen-
eration on pathology is directly related to a dysregulation of
noradrenaline, or indirectly related via neuroinflammatory
mechanisms or alterations in additional LC neuromodulators,
such as brain-derived neurotrophic factor or galanin, requires
further investigation (Chalermpalanupap et al., 2017; Betts
et al., 2018). Interestingly, there is also evidence of noradrener-
gic hyperactivity in early disease (as reviewed by Weinshenker
et al., 2018), consistent with a number of reports of elevated
levels of CSF noradrenaline and/or noradrenaline turnover in
Alzheimer’s disease (Palmer et al., 1987; Hoogendijk et al.,
1999). Thus, hyperactivity in a structurally impaired LC
might further accelerate the propagation of neuropathology
in neurodegenerative disease via noradrenergic projections
(Weinshenker, 2018). As such, early detection of LC decline
using in vivo imaging techniques might contribute to earlier
diagnosis, and support personalized pharmacological interven-
tions to alleviate compensatory hyperactivity of the noradren-
aline system and potentially slow down disease progression.
Recent advances in non-invasive neuroimaging techniques
now permit the in vivo assessment of the LC using MRI
(Sasaki et al., 2006; Keren et al., 2009; Clewett et al.,
2016; Betts et al., 2017; Priovoulos et al., 2018) opening
the possibility to track LC changes as a biomarker for nor-
adrenergic dysfunction. The utility of this approach for clin-
ical research will depend on whether LC imaging in
combination with established biomarkers, can help to better
stage neurodegenerative diseases and characterize biomarker-
positive individuals before the onset of dementia. LC imaging
could also have important implications in clinical trials as a
stratification tool for predicting treatment success of pharma-
cological intervention studies targeting the noradrenergic
system. This article reports on the consensus reached at the
first European Locus Coeruleus Imaging meeting held in
Magdeburg in 2018. It describes the challenges for
establishing LC MRI measures as a biomarker for diagnosis
and targeting therapeutic interventions in neurodegeneration
and outlines a strategy for obtaining reliable, biologically
validated and clinically suitable imaging approaches.
As discovered over a decade ago (Sasaki et al., 2006), the
LC is visualized using MRI scanning protocols that are
sensitive to a paramagnetic compound called neuromelanin,
which accumulates in noradrenergic neurons, and may be
taken as an indicator of LC integrity (i.e. cell density).
While neuromelanin-sensitive MRI is a relatively new tech-
nique, a number of studies have shown that MRI can detect
signal differences in the LC between healthy controls and
diseases with known LC involvement (e.g. in major depres-
sion, Parkinson’s disease and Alzheimer’s disease as re-
cently reviewed by Liu et al., 2017). Given, however, the
substantial interindividual differences in LC measures
across healthy older adults (Liu et al., 2017, 2019), further
studies are required to establish whether LC degeneration
can be reliably detected in vivo (Liu et al., 2017; Sulzer
et al., 2018). Furthermore, to clarify whether interindivi-
dual variability in LC integrity is related to varying levels
of neuropathologies (e.g. tau, amyloid or -synuclein), stu-
dies using LC MRI in combination with in vivo measure-
ments of pathology (e.g. PET and CSF biomarkers) in
cognitively normal older adults and patients are required.
While these studies are currently underway, first results in
ageing and early-stage Alzheimer’s disease indicate that LC
MRI contrast is indeed modulated by both tau and amyloid
pathology. Recent evidence demonstrating that LC MRI
contrast is associated with CSF amyloid (amloid-b42/40) in
early-stage Alzheimer’s disease (Betts et al., 2019) and tau
pathology at higher levels of amyloid burden using tau and
amyloid PET, respectively (Jacobs et al., 2018a), may par-
tially explain the interindividual variability in LC integrity
observed in old age. Interestingly, post-mortem studies
using 18F-AV-1451 tau PET have also shown off-target
binding properties to neuromelanin in the substantia
nigra (Marquie´ et al., 2015; Hansen et al., 2016). Thus
18F-AV-1451 may also be capable of imaging neurodegen-
eration. However, such changes may be difficult to inter-
pret because of the mixed PET signal generated by on-
target binding to tau tangles and off-target binding to neu-
romelanin, which would likely also be age-dependent.
Practical considerations in
in vivo locus coeruleus
imaging
The intrinsic neuromelanin-driven contrast that allows us
to visualize the LC using MRI was first identified in vivo as
hyperintensity on 2D T1-weighted turbo spin echo (TSE)
images (Sasaki et al., 2006). These hyperintensities corres-
pond closely with areas of higher concentration of neuro-
melanin (Keren et al., 2015), suggesting that the high signal
intensities in the LC are driven by neuromelanin. In support
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of this, a recent study has shown that the neuromelanin
concentration in the substantia nigra is linearly related to
neuromelanin-MRI contrast and resting blood flow in the
substantia nigra (Cassidy et al., 2019). The observation
that LC MRI acquisitions are subject to incidental magnet-
ization transfer (MT) effects (Dixon et al., 1990) and that
dedicated MT preparation increases neuromelanin-related
contrast, have led several authors to credit MT as the pri-
mary source of LC contrast in MRI (Nakane et al., 2008;
Priovoulos et al., 2018). Recent findings suggest that an
interaction of (higher) intracellular water content with
paramagnetic ions (such as neuromelanin) may set the LC
apart from its surroundings in MT-weighted imaging
(Watanabe et al., 2019). Moreover, paramagnetic ions in
addition to neuromelanin may contribute to this effect as
structures low in neuromelanin (e.g. periaqueductal grey
matter) demonstrate similar MRI contrast to the LC using
MT-weighted imaging (Cassidy et al., 2019; Watanabe
et al., 2019). Despite the different approaches that have
successfully visualized the LC (Fig. 1), a precise understand-
ing of the underlying contrast mechanism is thus still lack-
ing. As outlined in more detail below, a combination of
histological and post-mortem imaging studies would pro-
vide important insights in this regard. Mechanisms invol-
ving both neuromelanin concentration and macromolecules
in the LC and surrounding tissues may be active simultan-
eously, and a combination of mechanisms may be required
to explain the contrast patterns seen in normal ageing and
in pathology. A relevant aspect for imaging neuromelanin
is that it is known to scavenge metals both across the life-
span and in disease states (Zecca et al., 2004; Biesemeier
et al., 2016). In vitro studies, albeit with synthetic melanin,
suggest that T1 shortening in the LC may be driven by
compounds of neuromelanin and chelated metals, such as
iron and copper (Enochs et al., 1989, 1997; Trujillo et al.,
2017) impacting the macromolecule-bound pool, rather
than neuromelanin or iron alone (Langley et al., 2015;
Trujillo et al., 2017). It has therefore been proposed that
complexes of neuromelanin-bound paramagnetic ions are
the primary drivers of LC contrast (Enochs et al., 1989;
Nakane et al., 2008; Trujillo et al., 2017); however, neu-
romelanin itself, even free of metals, is paramagnetic
(Shima et al., 1997). Indeed, at least in vivo, LC contrast
does not seem to benefit from typical iron-sensitive con-
trasts, such as quantitative susceptibility mapping (QSM)
or apparent R2* (Acosta-Cabronero et al., 2016; Betts
et al., 2016, respectively) (Fig. 1N and R).
More recently, MT preparation and/or T1-weighting have
been combined, both with short repetition time spoiled gra-
dient echo and turbo-flash readouts, to increase spatial
resolution and/or shorten the acquisition time compared
to TSE acquisitions (Chen et al., 2014; Betts et al., 2017;
Ha¨mmerer et al., 2018; Priovoulos et al., 2018). The small
size of the LC has motivated the use of high spatial reso-
lution, at least in-plane, while high isotropic resolution
minimizes partial volume effects (i.e. inclusion of non-LC
tissue within a putative LC voxel). However, this comes at
the cost of relatively low signal- and contrast-to-noise ratio
(SNR and CNR, respectively) due to smaller voxel sizes
and higher vulnerability to subject motion, which has
prompted averaging over multiple repetitions. Anisotropic
voxels, which mimic the shape and orientation of the LC,
have capitalized on the elongated shape of the LC to in-
crease SNR and shorten scan times. Given the tilted and
not perfectly cylindrical nature of the LC, this strategy is
prone to errors at the most rostral and caudal ends of the
structure leading to biases in segmentation and volumetric
measurements (Liu et al., 2017). Alternatively, isotropic ac-
quisitions that capture the entire rostrocaudal length of the
LC have also been proposed (Betts et al., 2017; Priovoulos
et al., 2018) and may be more consistent with ex vivo
measurements compared to anisotropic scans (Liu et al.,
2017). While the increased SNR with ultra-high field
MRI (i.e.5 7.0T) offers higher attainable spatial resolution
and/or shorter acquisition times, increased specific absorp-
tion rates means that higher power acquisitions, e.g. those
using MT preparation pulses or high flip angles, might not
be readily available thereby necessitating further optimiza-
tion (Priovoulos et al., 2018) (see also Box 2 for recom-
mendations on how to use currently available sequences).
Validating in vivo locus
coeruleus imaging using
post-mortem MRI and
histology
A key aim of conducting LC imaging in clinical groups is to
capture in vivo disease-related physiological and structural
changes such as reductions in neuronal density. Several val-
idation strategies, including a combination of post-mortem
magnetic resonance microscopy and histological labelling
(Forstmann et al., 2017), have thus been proposed to
shed new light into the underlying biological processes driv-
ing in vivo imaging results. Such approaches, however, are
also technically challenging. Tissue fixation and embedding
media can affect the properties of post-mortem tissue and
strongly influence the MRI signal (Dusek et al., 2019).
Thus, the same tissue properties might be expressed differ-
ently in post-mortem and in vivo MRI. For instance, tissue
fixation causes strong T1 and T2 shortening that is add-
itionally dependent on the choice of fixative agent and fix-
ation time (Birkl et al., 2016, 2018). Contrast changes also
arise if the temperature used for post-mortem scanning dif-
fers from 37C (Birkl et al., 2014). Differences between
in vivo and post-mortem tissue could also be driven by
changes in metal oxidation states during fixation or by re-
distribution of iron and other metals across macromol-
ecules (e.g. proteins, neuromelanin, etc.) (Shima et al.,
1997; Krebs et al., 2014). It should be considered that
iron is bound in brain tissue in different molecular forms
such as ferritin, neuromelanin, hemosiderin and others,
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Figure 1 Overview of LC visibility using post-mortem and in vivo MRI. The LC can be imaged in post-mortem tissue using numerous
MRI protocols [arrows indicate the LC, evident as dark spots in T2* (A and G) and bright spots in T1-weighted (E) and MT-weighted (F) scans] in
addition to using histological techniques. (D) The LC is visible as dark spots in a post-mortem slice without any staining, due to neuromelanin
deposits, which are thought to contribute to magnetic resonance visibility of the LC. (C) Myelination in the LC area. The LC and central pontine
grey show very low myelination, but are surrounded by areas with very high and intermediate myelination (green areas), possibly also contributing
to MR visibility of the LC. To image the LC in vivo, T1-weighted (H, O and S) and MT-weighted (I–K) MRI protocols can be used (arrows indicate
the LC, evident as bright spots in T1-weighted and MT-weighted scans). Using these protocols, a decline in LC integrity in Alzheimer’s disease
dementia (S) compared to healthy elderly adults (O) can be identified (Betts et al., 2019). To fine-tune these scan protocols further, it is necessary
to understand the magnetic resonance contrast mechanisms that underlie LC visibility. (L–N and P–R) Quantitative maps which isolate different
magnetic resonance contrast effects (R1, MT and R2* effects), show that LC visibility in T1-weighted as well as MT-weighted scans in vivo is mostly
due to R1 effects (mean LC visibility across 22 healthy older adults extracted from line regions of interest; see inset on right for position of line
regions of interest. Black dots indicate position of maximal signal intensity based on T1-weighted maps. Peaks in signal intensity are apparent in R1
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(continued)
each having different physico-chemical properties (Ward
et al., 2014). Thus, LC contrast observed in vivo using
neuromelanin-sensitive MRI at clinical field strength
cannot be easily replicated with post-mortem magnetic res-
onance microscopy at lower temperature (T4 21C) and
ultra-high magnetic field strengths (57.0T). In particular,
T2*/R2* measurements of the LC return markedly different
values in vivo and post-mortem tissue. Whil they often
afford the best visibility in post-mortem tissue (Fig. 1A
and G), T2* effects are not evident in individual in vivo
samples and are comparatively weaker than R1 effects in
group analyses (Fig.1L–N and P–R). However, by adjusting
acquisition parameters, it is still possible to observe the
characteristic T1- and MT-weighted hyperintensity of the
LC in in vivo (Fig. 1H–K, O and S) and ex vivo MRI
(Fig. 1E and F). To address comparability issues, future
post-mortem MRI studies focusing on the LC could com-
bine quantitative T1, T2*, MT and QSM with tight control
of the post-mortem fixation time and iron and metal
concentrations in the fixation solution in order to relate
magnetic resonance signal intensities to stereological and
quantitative histological measures (e.g. myelin, lipids, neu-
rons, iron, neuromelanin, copper, and iron- and copper-
containing proteins).
Using a combination of histology and post-mortem MRI
in the LC, a recent study explored whether neuromelanin-
sensitive MRI contrast could serve as a proxy measure of
LC ‘integrity’ (i.e. neuronal density in the LC). The authors
showed that areas of LC hyperintensity in T1-weighted
MRI were co-localized with neuromelanin-rich neurons in
the LC region (Keren et al., 2015), suggesting that LC visi-
bility in MRI may indeed be driven by the neuromelanin
content of noradrenergic neurons. Similarly, studies using
neuromelanin-sensitive MRI could show that age-related
cross-sectional patterns in in vivo signal intensity across
the lifespan (Shibata et al., 2006; Jacobs et al., 2018a;
Liu et al., 2019) replicate the inverted U-shaped cross-
sectional development of neuromelanin deposits in the LC
observed in post-mortem tissue (Mann and Yates, 1974,
but see Ohm et al., 1997; Zecca et al., 2004 for studies
reporting a stable level of neuromelanin-containing neurons
or linear increase of neuromelanin content in LC tissue
across the lifespan, respectively). This inverted U-shaped
pattern has been suggested to reflect increasing neuromela-
nin content due to continuous noradrenaline production
during adulthood prior to ensuing cell death and clearance
of released intracellular neuromelanin with the advent of
age-related neurodegeneration and onset of disease (Mann
and Yates, 1974). Indeed, post-mortem data suggest that
neuromelanin may be a more suitable indicator of neuronal
density in older adults (at least4 55 years) as younger
adults’ LC neurons may not yet be sufficiently pigmented
with neuromelanin to allow inference on cell numbers in
neuromelanin-sensitive MRI (Manaye et al., 1995; Liu
et al., 2019). Nonetheless, further studies are warranted
to investigate whether higher signal intensities in older
adults invariably represent more intact LC neurons in the
LC, and whether additional mediating factors for interpret-
ing LC-related MRI signals must be considered in different
age groups or clinical populations. For instance, patho-
logically altered proteins, such as hyperphosphorylated or
aggregated tau, which are well known markers of ageing
and neurodegenerative disease as well as non-pathological
proteins and lipids, are additional important constituents of
neuromelanin pigments (Engelen et al., 2012; Zucca et al.,
2018) that accumulate in specific organelles in the LC as
occurs in substantia nigra (Zecca et al., 2004; Braak et al.,
2011; Zucca et al., 2017). However, the effect of these
constituents on LC MRI contrast has not yet been system-
atically explored.
Outlook and conclusion
A major goal of in vivo LC imaging in clinical research is
to aid differential diagnosis, disease monitoring and strati-
fication to novel treatments. As such, LC imaging has the
potential to become a component of a precision medicine
approach to neurodegenerative diseases. As brain function
adapts to ensuing pathology, such as receptor increases in
target areas of noradrenergic LC projections or increased
connectivity following a decline in LC function (Herrmann
et al., 2004; Ye et al., 2015), LC imaging could provide a
stratification tool for predicting treatment success of
pharmacological intervention studies targeting the noradre-
nergic system (Ye et al., 2015, see also Fig. 2). Once its
relationship to pathogenic changes (e.g. -synuclein or tau
aggregation) has been determined, it could also support
differential diagnosis and be added to the portfolio of lon-
gitudinal monitoring staging tools for neurodegenerative
diseases. Over the next years, we expect substantial pro-
gress towards these goals through a multidisciplinary
Figure 1 Continued
and to some extent in R2* maps (Ha¨mmerer et al., 2018a)]. Sequence details/ stains: (A) 7 T T2*-weighted (50 mm resolution) FLASH MRI image
TE = 19 ms; (B) TH staining for LC neurons (dark); (C) Luxol fast blue staining for myelinated fibres in same slice (green); (D) Block face image
after celloidin embedding (LC neurons dark); (E) 7 T T1-weighted (0.2  0.2  2 mm) TSE image (TE/TR/TI = 11/3000/825 ms); (F) 7 T MT-
weighted FLASH MRI image (TE/TR = 5.1/26 ms); (G) 7 T T2*-weighted FLASH image (TE/TR = 21/30 ms) (Otaduy et al., unpublished results);
(H) 3 T T1-weighted (0.4  0.4  3 mm) FLASH image (TE/TR = 3.35–16.95/27) averaged across six repetitions; (I) 3 T MT-weighted
(0.4  0.4  3 mm) FLASH image (TE/TR = 3.35–16.95/30.74); (J) 7 T MT-TFL image (0.4  0.4  0.5 mm); (K) 3 T MT-weighted (1.5 mm3) SPGR
image (TE/TR = 5 ms/30 ms; (O and S) 3 T T1-weighted (0.75 mm
3) FLASH image (TE/TR = 5.56 ms/20 ms). Image in J is reproduced with
permission from Priovoulos et al. (2018); O is reproduced with permission from Betts et al. (2017). TE/TR/TI = echo time/repetition time/
inversion time.
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Box 2 Practical suggestions for in vivo LC imaging
Sequences
The LC is most visible using T1- or MT-weighted structural sequences and can be well characterized using 3 T and 7 T MRI (see Betts et al., 2017;
Priovoulos et al., 2018 and Liu et al., 2017 for a recent review). To date, there is no single ‘best’ sequence for LC imaging: there is a trade-off
between non-quantitative protocols offering easier LC localization, and quantitative magnetic resonance acquisitions that provide more objective
biophysical measures of brain tissue but with lower localization ability compared to dedicated LC sequences.
Voxel size
Owing to the small size of the LC (15 mm in length and 1–3 mm in diameter), larger voxel sizes should be avoided as they result in weaker signals
owing to partial volume effects with tissue outside the LC within the voxel. On the other hand, voxel volumes lower than 0.4–0.5 mm3 run the risk
of lacking sufficient signal-to-noise ratio, given the current sensitivity of neuromelanin-sensitive magnetic resoance sequences. If more accurate LC
volume assessments (with less partial volume contamination) are desired, isotropic voxels sizes are preferable [e.g. 0.75mm  0.75mm 0.75mm are
possible at 3T (Betts et al., 2017) and 0.4mm 0.4mm 0.5mm at 7 T (Priovoulos et al., 2018)]. These, however, can make identification of individual
LCs harder because of lower signal-to-noise ratio, requiring a group template approach (see below). If reliable identification of individual LCs is
desired but accurate volume assessments are less critical, anisotropic voxel sizes (e.g. 0.5 mm  0.5 mm in plane resolution  2 mm slice thickness)
can be used to exploit the quasi-cylindrical shape of the LC and maximize signal-to-noise ratio at the cost of greater partial volume errors in
peripheral LC voxels (Liu et al., 2017).
Acquisition
It is recommended that the field-of-view is aligned perpendicular to the dorsal edge of the pons such that cylindrical voxels align with the LC.
Motion artefacts
Great care should be taken to reduce head motion during the MRI acquisition. A thin pillow placed on the base of the coil to ensure tight fixation
and patient comfort can help minimize motion and achieve high measurement precision e.g. improving coregistration across/within individuals e.g.
between structural and functional data. Shorter acquisition times which are less prone to motion artefacts can be achieved by using a reduced field-
of-view comprising the brainstem only and by relying on offline-averaging of scans (Chen et al., 2014). Typical scan durations for smaller field-of-view
acquisitions take approximately half the time of whole-brain acquisitions and range between 5 and 9 min at 3 T and 7 T MRI, respectively (Liu et al.,
2017; Priovoulos et al., 2018). However, template-based segmentation approaches (see below) are more challenging with reduced field-of-view
acquisitions than with whole brain scans (but see Dahl et al., 2019).
Post-processing
Semi-automated LC segmentation can be performed through highly iterative co-registration resulting in a high definition group-average template
where the LC can be reliably identified. The resultant template LC region of interest can then be spatially transformed to each individual’s native
space (Betts et al., 2017; Liu et al., 2019). When using template-based approaches however, care must be taken to minimize the impact of
coregistration inaccuracies and additional user intervention might be required. There are at present differing views on whether LC segmentation
should be performed manually or automatically, and on whether LC measurements should encompass the whole structure or favour partial
extraction to avoid potential contamination. Chen et al. (2014) argued that automated segmentation approaches might be less error-prone and
may thus lead to higher consistency across scans and studies, and that visually locating the LC as the highest-intensity voxel at either side of the
fourth ventricle (on the axial plane) might be susceptible to noise-related errors. In contrast, Keren et al. (2009) argued that assessing single voxels
might be more reliable in that it does not rely on boundary definitions or signal intensity thresholding, thereby leading to improved sensitivity to
overall LC differences. To date, however, no study has systematically compared manual and automated methods.
Reference normalization
An important limitation of MRI is that it produces arbitrarily scaled greyscale images that are suboptimal for intersubject comparisons because
normalization to a proximal control region (often the pontine tegmentum) becomes necessary (Betts et al., 2017; Liu et al., 2017; Ha¨mmerer et al.,
2018). However, the reference tissue may also change throughout the lifespan, or be abnormal in neurodegenerative diseases (Keren et al., 2009;
Clewett et al., 2016). Furthermore, asymmetric signal-intensity biases in the LC and surrounding tissue have been reported both in healthy subjects
and Parkinson’s disease patients (Keren et al., 2009; Garcia-Lorenzo et al., 2013; Betts et al., 2017; Tona et al., 2017), in apparent contradiction with
post-mortem studies that show largely symmetric distributions of neuromelanin-pigmented cells in the LC (German et al., 1988; Baker et al., 1989;
Chan-Palay and Asan, 1989; Ohm et al., 1997). It is therefore imperative to avoid instrumental biases such as transmit and receive field inhomo-
geneities, and ensure asymmetries are not introduced by the methodology. To this end, quantitative (parametric) MRI (Weiskopf et al., 2013) has
shown promise by quantifying specific tissue properties in terms of physical units and may now be used for quantitative LC imaging (Fig. 1L–N and
P–R) (Ha¨mmerer et al., 2018a). Moving forward, one may speculate that multi-parametric mapping might be preferred to single-contrast assessments
for a more complete view of LC status and greater insight into underlying contrast mechanisms, especially if performed within the population-
specific time constraints.
Age comparisons and control groups
Owing to an age-related increase in neuromelanin content in LC cells as well as LC signal intensity using neuromelanin-sensitive MRI, LC imaging
may be suboptimal in younger adults, likely due to reduced neuromelanin levels compared to older adults (Zecca et al., 2004, 2006; Liu et al., 2019).
For the same reason, interpreting age differences in LC MRI contrast between young and older adults as age differences in LC integrity may be
problematic. In a large cross-sectional dataset, a decline in LC integrity was only observed at 60 years of age and over (Liu et al., 2019). At present
it is unclear if neuromelanin-sensitive MRI can detect a reduction in LC integrity below this age range. Moreover, within an ageing sample, control
groups must be tightly matched for age to the clinical population under investigation.
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collaboration of experts in neurodegenerative diseases, ima-
ging, neuropathology and cognition.
As neuromelanin accumulates in the cell bodies of LC
neurons, neuromelanin-sensitive MRI can only inform on
changes in cell density but not changes in synaptic density
or cell activity. It is known from post-mortem studies that
cell numbers in the LC decline with advancing Alzheimer’s
disease pathology (Theofilas et al., 2017). However, prior
to cell loss, changes in synaptic density in the LC and/or
neuronal activity should be considered. Post-mortem and
lesion studies suggest that noradrenaline production in re-
maining LC neurons may increase following degeneration
of LC neurons (for a review see Weinshenker et al., 2018).
At present, it is not known whether synaptic density is
altered prior to or in tandem with cell loss in the LC. It
would be interesting to use novel PET tracers of synaptic
density (Finnema et al., 2016) in combination with LC
imaging to assess how differences in LC synapse density
relate to LC MRI contrast in neurodegenerative diseases.
Direct and indirect functional measures of LC activity or
noradrenaline release can be assessed using high resolution
functional MRI, pupillometry, PET measures of noradren-
ergic transporter levels (Sommerauer et al., 2018), or by
assessing noradrenaline levels in CSF. These measures,
however, are not short of caveats. PET and functional
MRI measures provide noisy assessments given the small
size of the LC. Moreover, the LC is also know to release
dopamine and GABA (Kempadoo et al., 2016; Takeuchi
et al., 2016; Breton-Provencher and Sur, 2019), thus dopa-
mine and GABA levels may also need to be assessed in
conjunction with noradrenaline levels when characterizing
LC function. Finally, it can also be difficult interpreting
functional activation in the LC as an indicator of neuronal
capacity since activation will not only depend on the
Figure 2 Establishing LC imaging as a biomarker for noradrenergic dysfunction. LC imaging offers potential as a disease monitoring
and stratification tool to predict the success of novel pharmacological ligands in clinical trials. To achieve this aim, it will be essential to validate
in vivo LC MRI contrast with respect to the concentration of neuromelanin and density of noradrenergic neurons in post-mortem tissue. This will
be important for developing a deeper understanding into how changes in LC MRI contrast both in vivo and in post-mortem tissue correlate with
neuromelanin-bound metals in noradrenergic neurons and is influenced by the neuropathological characteristics of neurodegenerative diseases. In
the clinic, longitudinal LC imaging may be combined with biomarkers (e.g. in CSF or molecular imaging) to assess how changes in LC MRI contrast
may drive clinical and pathological manifestations of neurodegenerative diseases. Source of CSF image: Wikimedia Commons; molecular imaging
figure is adapted from Palmqvist et al. (2017); LC integrity image (middle) adapted with permission from Betts et al. (2017); age effects on LC
integrity image (right) reproduced with permission from Liu et al. (2019).
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number of neurons or synaptic density, but also on the
degree in which the LC is engaged during the processing
of the task at hand [i.e. the strength and the nature of the
experimental manipulation, e.g. as suggested previously by
Ha¨mmerer et al. (2018)]. Nonetheless, synaptic density and
functional activation may be superior indicators of cogni-
tive impairment than cell pathology (Terry et al., 1991). As
the specificity of functional and experimental manipulations
for the LC increases, these measures may contribute valu-
able additional data on the role of the LC in neurodegen-
erative diseases.
One of the main tasks ahead for LC research lies in
setting up carefully designed longitudinal studies in healthy
ageing and disease cohorts with deep cognitive and physio-
logical phenotyping (e.g. the DELCODE study; Jessen
et al., 2018) to assess how LC integrity is related to cog-
nitive symptoms and functional brain changes at the ear-
liest stages of neurodegeneration. Previous work assessing
the reproducibility of LC imaging by quantifying the sta-
bility of LC contrast across two or more independent scan
sessions has revealed moderate to high reproducibility
(Langley et al., 2017; Tona et al., 2017; Betts et al.,
2017; Dahl et al., 2019). Therefore to achieve reliable lon-
gitudinal testing in the future will require an improvement
in the reproducibility and reliability of LC imaging tech-
niques. To assess how the LC modulates the function of
distributed brain networks at rest and during cognitive
tasks, will require further optimization of existing func-
tional MRI sequences to overcome the challenges of brain-
stem imaging (Du¨zel et al., 2015) and inclusion of
additional physiological information (see Liu et al., 2017
for recommendations). In addition, experimental tasks that
elicit robust LC signals require development (Mather et al.,
2016; Liu et al., 2017; Clewett et al., 2018).
Second, future studies should test whether LC imaging is
related to disease progression in neurodegenerative diseases.
This will require characterizing the relationship between LC
MRI measures and neuropathology (e.g. with respect to
amyloid, tau or alpha-synuclein using CSF biomarkers or
PET) but also noradrenergic function using noradrenergic
PET-tracers including those to assess noradrenergic trans-
porter density (Sommerauer et al., 2018). However, ad-
vances in analysis (to maximize spatial resolution) and
exclusion of potential off-target binding sites (Lee et al.,
2018) must accompany ligand development. For optimizing
and validating LC MRI further, greater synergy between
in vivo, post-mortem, in vitro and clinical studies is
required for a deeper understanding into how LC MRI
contrast relates to the pathophysiology of different neuro-
degenerative diseases (Fig. 2). Such studies will also benefit
from using clinically informed test beds, i.e. populations,
that show a clear difference in relevant tissue properties,
e.g. between young and older adults but also in neurode-
generative diseases, such as Alzheimer’s disease and beyond
(Box 1).
Finally, a growing body of knowledge on similarities and
differences between neuromelanin deposits in noradrenergic
cells in the LC and dopaminergic cells in the substantia
nigra (Zecca et al., 2004; Zucca et al., 2006; Wakamatsu
et al., 2015) open further avenues for using in vivo neuro-
melanin-sensitive MRI to also investigate the involvement
of the substantia nigra in tandem with the LC in a wide
range of clinical conditions, i.e. in diseases also affecting
the dopaminergic system, such as Parkinson’s disease
(Sulzer et al., 2018).
In conclusion, there is rapid progress towards achieving
more sensitive and high-resolution in vivo imaging of the
LC. The methods are non-invasive and fast enough to be
well tolerated using high (3T) or ultra-high (57T) MRI,
and can have great potential to inform the effectiveness of
psychopharmacological probes, therapeutic trials, and
physiological monitoring in clinical populations. We antici-
pate rapid growth in the evidence base for developing LC
imaging as a biomarker in neurodegenerative diseases.
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